StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

Exelixis r&d expenses

Research and development expenses are spending on new products and technology.

Exelixis's R&D Expenses for the twelve months ending Oct 2, 2026 was $834.63M, down 3.0% year over year. For fiscal 2025 it was $825.00M, down 9.4% from the year before. Over ten years it grew 24.0% a year on average. The highest annual figure on record is $1.04B in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Jan 2, 2026$825.00M-9.4%
FY2024Jan 3, 2025$910.41M-12.8%
FY2023Dec 29, 2023$1.04B+17.1%
FY2022Dec 30, 2022$891.81M+28.6%
FY2021Dec 31, 2021$693.72M+26.6%
FY2020Jan 1, 2021$547.85M+62.6%
FY2019Jan 3, 2020$336.96M+84.9%
FY2018Dec 28, 2018$182.26M+62.5%
FY2017Dec 29, 2017$112.17M+16.9%
FY2016Dec 31, 2016$95.97M-0.4%
FY2015Dec 31, 2015$96.35M-49.0%
FY2014Dec 31, 2014$189.10M+5.8%
FY2013Dec 31, 2013$178.76M+38.7%
FY2012Dec 31, 2012$128.88M-17.8%
FY2011Dec 31, 2011$156.84M-25.6%
FY2010Dec 31, 2010$210.68M-10.2%
FY2009Dec 31, 2009$234.70M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$209.48M+5.2%
Q2 FY2026Jul 3, 2026$211.99M+5.8%
Q1 FY2026Apr 3, 2026$199.92M-5.8%
Q4 FY2025Jan 2, 2026$213.25M-14.4%
Q3 FY2025Oct 3, 2025$199.16M-10.5%
Q2 FY2025Jul 4, 2025$200.36M-5.1%
Q1 FY2025Apr 4, 2025$212.23M-6.8%
Q4 FY2024Jan 3, 2025$249.00M+1.8%
Q3 FY2024Sep 27, 2024$222.57M-33.1%
Q2 FY2024Jun 28, 2024$211.15M-9.2%
Q1 FY2024Mar 29, 2024$227.69M-2.8%
Q4 FY2023Dec 29, 2023$244.67M-27.4%
Q3 FY2023Sep 29, 2023$332.59M+67.3%
Q2 FY2023Jun 30, 2023$232.57M+16.6%
Q1 FY2023Mar 31, 2023$234.25M+49.5%
Q4 FY2022Dec 30, 2022$336.82M+51.5%
Q3 FY2022Sep 30, 2022$198.84M+21.7%
Q2 FY2022Jul 1, 2022$199.48M+34.1%
Q1 FY2022Apr 1, 2022$156.67M-1.6%
Q4 FY2021Dec 31, 2021$222.27M+44.1%
Q3 FY2021Oct 1, 2021$163.37M-7.6%
Q2 FY2021Jul 2, 2021$148.79M+29.5%
Q1 FY2021Apr 2, 2021$159.29M+56.4%
Q4 FY2020Jan 1, 2021$154.28M+63.3%
Q3 FY2020Oct 2, 2020$176.76M+81.7%
Q2 FY2020Jul 3, 2020$114.93M+40.3%
Q1 FY2020Apr 3, 2020$101.88M+61.0%
Q4 FY2019Jan 3, 2020$94.45M+64.9%
Q3 FY2019Sep 27, 2019$97.30M+117.5%
Q2 FY2019Jun 28, 2019$81.93M+92.8%
Q1 FY2019Mar 29, 2019$63.29M+67.6%
Q4 FY2018Dec 28, 2018$57.27M+77.8%
Q3 FY2018Sep 28, 2018$44.74M+56.7%
Q2 FY2018Jun 29, 2018$42.49M+50.6%
Q1 FY2018Mar 30, 2018$37.76M+62.7%
Q4 FY2017Dec 29, 2017$32.20M+35.3%
Q3 FY2017Sep 30, 2017$28.54M–
Q2 FY2017Jun 30, 2017$28.21M–
Q1 FY2017Mar 31, 2017$23.21M–
Q4 FY2016Dec 31, 2016$23.80M–

More Exelixis figures

See a number that looks wrong?